Abstract

Recently, using gelatin nanoparticles as a biocompatible carrier in drug delivery systems is growing up. Drug delivery is one of the most common applications of nanoparticles in cancer treatment in order to optimize the drug efficiency. In this study, gelatin nanoparticles were firstly synthesized and loaded with tamoxifen that subsequently characterized by SEM, TGA and FT-IR analyses. The approximate drug loading efficiency was calculated about 17.43% for tamoxifen-loaded gelatin (TG). Then, the effect of TG on apoptosis induction and cytotoxicity of MCF-7 cell line was evaluated and compared with flow cytometry and MTT assay. The MTT results showed that tamoxifen and TG nanoparticles could inhibit the proliferation of MCF-7 cells in a dose-responsive manner, with an IC[Formula: see text] of IC[Formula: see text] of 200 [Formula: see text]g/mL and 50 [Formula: see text]g/mL after 24[Formula: see text]h and 48[Formula: see text]h, respectively. Moreover, from flow cytometric results, it can be suggested that TG nanoparticles are more potent in inducing apoptosis and cell death through programmed cell death. Actually, TG nanoparticles primarily increased the early apoptotic cells during the 24-h incubation period Our results revealed that tamoxifen-loaded gelatin nanoparticles are more potent than tamoxifen alone. These findings support the use of tamoxifen-loaded gelatin nanoparticles in target-specific therapy for cancer treatment.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.